Reuters logo
BRIEF-Amicus Therapeutics announces U.S. Regulatory pathway for Migalastat for Fabry Disease
November 28, 2016 / 9:25 PM / a year ago

BRIEF-Amicus Therapeutics announces U.S. Regulatory pathway for Migalastat for Fabry Disease

Nov 28 (Reuters) - Amicus Therapeutics Inc

* Amicus Therapeutics announces U.S. Regulatory pathway for migalastat for fabry disease

* Amicus Therapeutics Inc says regulatory plan for full approval pathway based on generation of additional gastrointestinal symptoms data

* Amicus Therapeutics Inc says intermediate expanded access program expected to begin in 2017

* Plans to collect additional data on gastrointestinal symptoms in fabry patients who have an amenable mutation Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below